Alps ETF Trust - Alps REIT Dividend Dogs ETF(NYSEMKT) GRI

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune disorders. The company is advancing its lead product candidate, GRI-0621, which is currently in phase IIa clinical trials for severe fibrotic lung diseases.

Products and Services

• GRI-0621: Oral inhibitor targeting type 1 Natural Killer T cells
• GRI-0803: Novel oral agonist for type 2 Natural Killer T cells
• Proprietary library of over 500 compounds for immune response modulation

Growth Outlook

• Phase IIa trials for GRI-0621 could lead to significant market opportunities
• Expansion into autoimmune disorder treatments with GRI-0803 in preclinical development
• Strong cash position of $11 million supports ongoing research and development

Financial Highlights

• Recent quarterly net income of -$1.998 million reflects ongoing investment in R&D
• Cash and cash equivalents increased to $11 million, providing operational stability
• Current ratio of 14.21 indicates strong liquidity and financial health

GRI Bio, Inc. is positioned in the biotechnology sector, focusing on innovative treatments for serious health conditions. The company’s lead candidate, GRI-0621, is undergoing critical clinical trials, which could pave the way for future revenue streams. The preclinical development of GRI-0803 further diversifies the product pipeline, targeting autoimmune disorders. Financially, GRI Bio maintains a robust cash position, which is essential for sustaining research and development efforts. The current ratio indicates a strong ability to meet short-term obligations, reflecting prudent financial management. Despite recent net losses, the focus on advancing clinical trials and expanding the product portfolio suggests a commitment to long-term growth and value creation.